{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T11:55:00Z","timestamp":1771674900632,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,21]]},"DOI":"10.7759\/cureus.30541","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T12:50:06Z","timestamp":1666356606000},"source":"Crossref","is-referenced-by-count":2,"title":["The Successful Treatment of COVID-19-Induced Bullous Pemphigoid With Dupilumab"],"prefix":"10.7759","author":[{"given":"Michelle A","family":"Savoldy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teja","family":"Tadicherla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zade","family":"Moureiden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noura","family":"Ayoubi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brooke T","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/biom10101432","article-title":"Bullous pemphigoid: trigger and predisposing factors","volume":"10","author":"Moro F","year":"2020","unstructured":"Moro F, Fania L, Sinagra JL, Salemme A, Di Zenzo G. Bullous pemphigoid: trigger and predisposing factors. Biomolecules. 2020, 10:1432. 10.3390\/biom10101432","journal-title":"Biomolecules"},{"key":"ref2","unstructured":"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid. (2021). Accessed. July 6, 2022: https:\/\/www.uptodate.com\/contents\/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoi...."},{"key":"ref3","unstructured":"Management and prognosis of bullous pemphigoid. (2021). Accessed. July 6, 2022: https:\/\/www.uptodate.com\/contents\/management-and-prognosis-of-bullous-pemphigoid."},{"key":"ref4","unstructured":"Dupilumab. drug information. (2022). Accessed: July 6, 2022: https:\/\/www.uptodate.com\/contents\/dupilumab-drug-information."},{"key":"ref5","unstructured":"Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid. (2021). Accessed. July 6, 2022: https:\/\/www.uptodate.com\/contents\/epidemiology-and-pathogenesis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid?...."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02907.x","article-title":"Characterization of skin cytokines in bullous pemphigoid and pemphigus vulgaris","volume":"140","author":"Rico MJ","year":"1999","unstructured":"Rico MJ, Benning C, Weingart ES, Streilein RD, Hall RP 3rd. Characterization of skin cytokines in bullous pemphigoid and pemphigus vulgaris. Br J Dermatol. 1999, 140:1079-86. 10.1046\/j.1365-2133.1999.02907.x","journal-title":"Br J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.5070\/D328257396","article-title":"A case of nivolumab-induced bullous pemphigoid successfully treated with dupilumab","volume":"28","author":"Bruni M","year":"2022","unstructured":"Bruni M, Moar A, Schena D, Girolomoni G. A case of nivolumab-induced bullous pemphigoid successfully treated with dupilumab. Dermatol Online J. 2022, 28:1-5. 10.5070\/D328257396","journal-title":"Dermatol Online J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15623","article-title":"Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: a case report","volume":"35","author":"Pop SR","year":"2022","unstructured":"Pop SR, Strock D, Smith RJ. Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: a case report. Dermatol Ther. 2022, 35:e15623. 10.1111\/dth.15623","journal-title":"Dermatol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.928621","article-title":"Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review","volume":"13","author":"Cao P","year":"2022","unstructured":"Cao P, Xu W, Zhang L. Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review. Front Immunol. 2022, 13:928621. 10.3389\/fimmu.2022.928621","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11123367","article-title":"Use of dupilumab in bullous pemphigoid: where are we now?","volume":"11","author":"Russo R","year":"2022","unstructured":"Russo R, Capurro N, Cozzani E, Parodi A. Use of dupilumab in bullous pemphigoid: where are we now?. J Clin Med. 2022, 11:3367. 10.3390\/jcm11123367","journal-title":"J Clin Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/110549-the-successful-treatment-of-covid-19-induced-bullous-pemphigoid-with-dupilumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:52:06Z","timestamp":1707508326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/110549-the-successful-treatment-of-covid-19-induced-bullous-pemphigoid-with-dupilumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.30541","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,21]]}}}